Michael Kennelly, MD
Urology · Charlotte, NCNPI 1720021637
Payments from drug & device makers
Across 1,706 payments — averaging $827.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$437K
- Medtronic$193K
- Coloplast$173K
- Boston Scientific$166K
- Sumitomo Pharma America, Inc.$146K
- Axonics, Inc.$124K
- plus $172K from 27 others
Across 5 payments — averaging $1131.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$3K
- Urotronic, Inc$3K
What the payments were for
- Consulting fees$388,37630%
- Speaking & faculty fees$690,62853%
- Travel & lodging$160,14212%
- Food & beverage$39,2943%
- Education$13,1161%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 477 | $437,102 |
| Medtronic(2 entities) | 342 | $192,570 |
| Coloplast | 101 | $173,370 |
| Boston Scientific | 247 | $165,895 |
| Sumitomo Pharma America, Inc. | 187 | $145,850 |
| Axonics, Inc. | 108 | $124,451 |
| Urovant Sciences Inc | 110 | $70,284 |
| C. R. Bard, Inc. & Subsidiaries | 40 | $29,141 |
| Astellas Pharma US Inc | 24 | $24,214 |
| Ipsen Innovation | 2 | $22,386 |
| Cook Research Incorporated | 11 | $11,247 |
| Laborie Medical Technologies Corp. | 8 | $7,368 |
| Ambu Inc. | 16 | $2,474 |
| Minze Health, Inc | 1 | $825 |
| Ambu A/s | 1 | $800 |
| Caldera Medical, Inc | 6 | $524 |
| Teleflex LLC | 1 | $350 |
| Olympus America Inc. | 4 | $322 |
| Contura, Inc. | 2 | $280 |
| Convatec Inc. | 3 | $249 |
| Procept Biorobotics Corporation | 1 | $223 |
| Ipsen Biopharmaceuticals, Inc | 2 | $181 |
| Avation Medical, Inc. | 2 | $176 |
| Neotract Inc. | 1 | $136 |
| Bluewind Medical | 1 | $130 |
| Valencia Technologies Corporation | 1 | $127 |
| AstraZeneca | 1 | $125 |
| Endo Pharmaceuticals Inc. | 1 | $122 |
| Travere Therapeutics, Inc. | 1 | $121 |
| Baxter Healthcare | 1 | $85 |
| 180 Medical, Inc. | 1 | $29 |
| Hollister Incorporated | 1 | $16 |
| ABC Home Medical Supply, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$419,391
- GEMTESA$192,348
- INTERSTIM$128,571
- Luja Coude$74,329
- SPEEDICATH$72,577
- Axonics$49,244
- GENERAL PELVIC ORGAN PROLAPSE$28,917
- Axonics r-SNM System$28,731
- SOLYX$25,002
- MYRBETRIQ$23,550
- ALTAVIVA$23,479
- XENFORM$18,480
- GENERAL - THERAPIES$14,645
- ADVANCE$13,151
- AMS$12,896
- Bulkamid$9,975
- Advantage System$8,625
- Solyx SIS System$6,917
- NURO$5,813
- AMS 700 CXR RTE KIT$4,575
How this compares
$1,411,188 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 172 | $135,966 |
| GemtesaVibegron | 155 | $126,506 |
| Solifenacin Succinate | 91 | $9,303 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 18 | $5,083 |
| Methenamine Hippurate | 31 | $2,746 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 12 | $2,265 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $1,447 |
| Silodosin | 11 | $1,279 |
| Trospium Chloride | 13 | $1,267 |
| Potassium Citrate ErPotassium Citrate | 11 | $1,080 |
| Estradiol | 20 | $1,046 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 24 | $822 |
| Desmopressin Acetate | 29 | $682 |
| Oxybutynin Chloride ErOxybutynin Chloride | 47 | $645 |
| Tamsulosin Hcl | 51 | $565 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $24,214 | $135,966172 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $145,850 | $126,506155 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.
Other urology in Charlotte
- Peter ClarkCharlotte$332K
- Samuel PeretsmanCharlotte$282K
- Justin MatulayCharlotte$150K
- Manish PatelCharlotte$84K
- Kris GastonCharlotte$32K
- Jeremy HubbardCharlotte$28K
- Todd CohenCharlotte$18K
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.